These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 31689158)
1. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis. Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158 [TBL] [Abstract][Full Text] [Related]
2. Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer. Tsao PA; Caram MEV Cancer J; 2020; 26(1):76-82. PubMed ID: 31977389 [TBL] [Abstract][Full Text] [Related]
3. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape. Kinsey EN; Zhang T; Armstrong AJ Cancer J; 2020; 26(1):64-75. PubMed ID: 31977388 [TBL] [Abstract][Full Text] [Related]
4. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer. Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195 [TBL] [Abstract][Full Text] [Related]
6. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Sydes MR; Spears MR; Mason MD; Clarke NW; Dearnaley DP; de Bono JS; Attard G; Chowdhury S; Cross W; Gillessen S; Malik ZI; Jones R; Parker CC; Ritchie AWS; Russell JM; Millman R; Matheson D; Amos C; Gilson C; Birtle A; Brock S; Capaldi L; Chakraborti P; Choudhury A; Evans L; Ford D; Gale J; Gibbs S; Gilbert DC; Hughes R; McLaren D; Lester JF; Nikapota A; O'Sullivan J; Parikh O; Peedell C; Protheroe A; Rudman SM; Shaffer R; Sheehan D; Simms M; Srihari N; Strebel R; Sundar S; Tolan S; Tsang D; Varughese M; Wagstaff J; Parmar MKB; James ND; Ann Oncol; 2018 May; 29(5):1235-1248. PubMed ID: 29529169 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. Wang L; Paller CJ; Hong H; De Felice A; Alexander GC; Brawley O JAMA Oncol; 2021 Mar; 7(3):412-420. PubMed ID: 33443584 [TBL] [Abstract][Full Text] [Related]
8. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841 [TBL] [Abstract][Full Text] [Related]
9. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. Mori K; Mostafaei H; Sari Motlagh R; Pradere B; Quhal F; Laukhtina E; Schuettfort VM; Kramer G; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF BJU Int; 2022 Apr; 129(4):423-433. PubMed ID: 34171173 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis. Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479 [TBL] [Abstract][Full Text] [Related]
11. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516 [TBL] [Abstract][Full Text] [Related]
12. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809 [TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN; Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173 [TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. Kassem L; Shohdy KS; Abdel-Rahman O Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505 [TBL] [Abstract][Full Text] [Related]
15. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513 [TBL] [Abstract][Full Text] [Related]
17. The evolving options in metastatic castration-sensitive prostate cancer. Hamilou Z Curr Opin Support Palliat Care; 2020 Sep; 14(3):270-275. PubMed ID: 32701855 [TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028 [TBL] [Abstract][Full Text] [Related]
20. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]